Full coverage· Health· Updated
New Pancreatic Cancer Drug Approved by FDA Faces Cost and Accessibility Hurdles
The FDA has approved Rasonque, a new drug for metastatic pancreatic cancer, offering extended survival but at a high cost.
2 newsrooms · 1 language · since
Plus
What happened
- 01FDA approves Rasonque for metastatic pancreatic cancer, extending survival.
- 02Drug costs $40,000 monthly, posing significant financial challenges.
- 03Personal import to Israel possible, but official approval and health basket inclusion are delayed.
- 04High costs may lead to increased insurance premiums or restricted coverage.
- 05Company stock surged, with significant market potential estimated.
- 06Doctors hope for broader application in other RAS-mutated cancers.
While accessible in Israel via personal import, official market entry and inclusion in the national health basket face significant delays and financial challenges, potentially impacting insurance coverage and patient costs.
The coverage
2 newsrooms on this story
Who covered it
- LeftNone
- Centre1
- RightNone
- HarediNone
- ArabNone
- Other1
How it broke
See which of the 2 newsrooms broke it, and who waited